Across TCGA pan-cancer cohorts, ZNF655 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ZNF655 data layer compared with 25 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in uterine carcinosarcoma (UCS), where higher ZNF655 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ZNF655 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

UCS, OV, and PRAD are the cancer types where ZNF655 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCS	OS	Median	III,IV	0.102	0.591	<.001	24	view →
OV	DFS	Median	III,IV	0.193	0.532	.015	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	DFS	Median	II,III,IV	0.915	0.439	.035	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: ZNF655 tumor-vs-normal RNA expression · all ZNF655 data types